Get started
Author

Scott Paulson

Observed names: MD Scott Paulson,, Paulson, Scott, Scott Paulson, MD
OpenAlex ID: A5111980609
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
2023 · Shubham Pant, Shubham Pant, et al. · The Lancet Oncology · 215
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study
2018 · Eric Liu, Scott Paulson, et al. · The Oncologist · 75
A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.
2022 · Thomas Adam Abrams, Syed Mohammad Ali Kazmi, et al. · Journal of Clinical Oncology · 20
Clinical Outcomes By Child-Pugh Class in Patients With Advanced Hepatocellular Carcinoma in a Community Oncology Setting
2023 · Abdalla Aly, Nicole Fulcher, et al. · Hepatic Oncology · 18
Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
2023 · Alison M Schram, Vivek Subbiah, et al. · Molecular Cancer Therapeutics · 13
Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)
2023 · Daneng Li, Yohann Loriot, et al. · EClinicalMedicine · 11
PDF
Neuroendocrine Carcinoma of the Prostate Gland
2016 · Pamela Hoof, Ginger Tsai-Nguyen, et al. · Baylor University Medical Center Proceedings · 10
PDF
Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study
2022 · Scott Paulson, David Ray, et al. · Oncology and Therapy · 9
PDF
Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy
2023 · Thorvardur R. Halfdanarson, Nadine Mallak, et al. · Cancers · 6
PDF
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.
2023 · Eileen Mary O'Reilly, Davide Melisi, et al. · Journal of Clinical Oncology · 4
Early esophageal neuroendocrine tumor
2021 · Heather Branstetter, Atin Agarwal, et al. · Baylor University Medical Center Proceedings · 3
GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction
2026 · Syed Sarmad Javaid, Muhammad Hanif, et al. · The American Journal of Cardiology · 2
The Impact of a Clinical Decision Support System for Advanced Gastric or Gastroesophageal Junction Cancer
2020 · Scott Paulson, Lisa M Hess, et al. · 2
HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network
2020 · Scott Paulson, Curtis Waycaster, et al. · Journal of the National Comprehensive Cancer Network · 1
Time for a change and to adopt a novel molecular genomic approach in NETs
2019 · Lisa Bodei, Eric Liu, et al. · Nature Reviews Clinical Oncology · 1
Tissue and ctDNA Genomic Profiling Identifies Determinants of Response in Advanced Esophagogastric Cancer: A Phase I/II Study of Abemaciclib plus Ramucirumab
2026 · Kelly, Ronan Joseph, Sherry, Christopher, et al. · Zenodo (CERN European Organization for Nuclear Research)
Modern approaches in neuroendocrine tumors (NETs).
2025 · Scott Paulson · PubMed
Activity of nab-sirolimus alone or in combination with cabozantinib, octreotide, or talazoparib in nonclinical neuroendocrine tumor models
2025 · Scott Paulson, Michael J. Demeure, et al. · Endocrine Abstracts
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
2025 · Scott Paulson, MD, Allen L. Cohn, MD, et al. · Endocrine Abstracts
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
2024 · Olivia Aranha, Milind M. Javle, et al. · Journal of Clinical Oncology
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
2023 · MD Michael J. Demeure,, MD Allen L. Cohn,, et al. · Endocrine Abstracts
Multicenter phase II study of abemaciclib and ramucirumab in metastatic esophageal/gastroesophageal junction carcinoma.
2022 · Ronan Joseph Kelly, Vincent K. Lam, et al. · Journal of Clinical Oncology
Works count: 22
Citation count: 390
H-index: 8
I10-index: 7
Year
Topic
Type